Dr Reddy’s Laboratories (DRL) has launched Bivalirudin injection which is indicated for use as an anti-coagulant in patients, after getting approval from the US health regulator.
Dr Reddy’s said in a BSE filing that it has “launched Bivalirudin for injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for injection, approved by the US Food and Drug Administration (USFDA).”
It said that its Bivalirudin injection, 250 mg/vial, is available in packages of 10 single-dose vials.
